Actuate Therapeutics, Inc. Common stock ACTU
Regular-session close
Pre-market · Nov 20, 4:18 AM ET
- YTD
- -96.51%
- 1 year
- -96.35%
5D -0.0684 (-21.38%)
- Market cap
- 12.91M
- EPS (ttm)
- -0.76
- Shares out
- 19.53M
- YTD return
- -96.51%
- 1-year return
- -96.35%
- 50-day average
- 8.35
- Volume
- 2.99M
- Avg volume
- 769.16K
- Open
- 0.2148
- Previous close
- 0.2456
- Day's range
- 0.1741 – 0.23
- 52-week range
- 0.1741 – 7.90
Key statistics
- 200-day average
- 8.07
- Enterprise value
- 268.98M
- Total cash
- 351.71K
- Total debt
- 6.90M
Fundamental scorecard
3 of 25 checks passed on ACTU’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- actuatetherapeutics.com
News
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session Actuate Therapeutics Announces Preclinical Data Demonstrating That Daily Oral Administration Of Elraglusib Achieved Up To 77% Tumor Growth Inhibition As Monotherapy In An Aggressive Melanoma Model
Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026 HC Wainwright & Co. Maintains Buy on Actuate Therapeutics, Lowers Price Target to $10
Actuate Therapeutics To Present New Clinical Data Of Oral Elraglusib At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
12 Health Care Stocks Moving In Tuesday's Intraday Session
Nasdaq Gains Over 150 Points; Coca-Cola Posts Upbeat Earnings Actuate Therapeutics Prices ~$11M Offering Of 30,986M Common Shares, Warrants At $0.71 Per Unit
Your note
Sign in to keep a note on ACTU — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AWM Investment Company, Inc. | 0.71% | 139,511 | 1.05M | Sep 29, 2024 |
| Long Corridor Asset Management Ltd | 0.64% | 125,000 | 941.25K | Sep 29, 2024 |
| Royal Bank of Canada | 0.18% | 35,300 | 265.81K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.14% | 27,893 | 210.03K | Sep 29, 2024 |
| Northwestern University | 0.14% | 27,778 | 209.17K | Sep 29, 2024 |
| KG&L Capital Management,LLC | 0.06% | 12,000 | 90.36K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.08% | 16,158 | 121.67K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.03% | 5,492 | 41.35K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.02% | 3,852 | 29.00K | Oct 30, 2024 |
